Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel Free CYRX Stock Alerts

CryoPort (CYRX) Competitors

CryoPort logo
$12.19 +1.98 (+19.39%)
Closing price 04:00 PM Eastern
Extended Trading
$12.14 -0.05 (-0.45%)
As of 05:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CYRX vs. PHVS, CAPR, GLPG, INBX, and SNDX

Should you be buying CryoPort stock or one of its competitors? The main competitors of CryoPort include Pharvaris (PHVS), Capricor Therapeutics (CAPR), Galapagos (GLPG), Inhibrx Biosciences (INBX), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry.

How does CryoPort compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

In the previous week, Pharvaris had 5 more articles in the media than CryoPort. MarketBeat recorded 22 mentions for Pharvaris and 17 mentions for CryoPort. Pharvaris' average media sentiment score of 0.14 beat CryoPort's score of -0.23 indicating that Pharvaris is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pharvaris
10 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
CryoPort
3 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

CryoPort has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PharvarisN/AN/A-$198.79M-$3.37N/A
CryoPort$176.18M3.47$78.30M$1.329.23

CryoPort has a net margin of 42.35% compared to Pharvaris' net margin of 0.00%. CryoPort's return on equity of -8.22% beat Pharvaris' return on equity.

Company Net Margins Return on Equity Return on Assets
PharvarisN/A -70.96% -64.18%
CryoPort 42.35%-8.22%-4.84%

Pharvaris has a beta of -2.34, meaning that its stock price is 334% less volatile than the S&P 500. Comparatively, CryoPort has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500.

Pharvaris presently has a consensus price target of $42.73, suggesting a potential upside of 42.33%. CryoPort has a consensus price target of $14.44, suggesting a potential upside of 18.44%. Given Pharvaris' higher probable upside, equities research analysts clearly believe Pharvaris is more favorable than CryoPort.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pharvaris
1 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.71
CryoPort
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.78

92.9% of CryoPort shares are held by institutional investors. 10.0% of CryoPort shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

CryoPort beats Pharvaris on 11 of the 15 factors compared between the two stocks.

How does CryoPort compare to Capricor Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

In the previous week, CryoPort had 7 more articles in the media than Capricor Therapeutics. MarketBeat recorded 17 mentions for CryoPort and 10 mentions for Capricor Therapeutics. Capricor Therapeutics' average media sentiment score of 0.27 beat CryoPort's score of -0.23 indicating that Capricor Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Capricor Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
CryoPort
3 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Capricor Therapeutics has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, CryoPort has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500.

CryoPort has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capricor TherapeuticsN/AN/A-$105.04M-$2.26N/A
CryoPort$176.18M3.47$78.30M$1.329.23

CryoPort has a net margin of 42.35% compared to Capricor Therapeutics' net margin of 0.00%. CryoPort's return on equity of -8.22% beat Capricor Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Capricor TherapeuticsN/A -67.52% -54.59%
CryoPort 42.35%-8.22%-4.84%

Capricor Therapeutics presently has a consensus price target of $46.09, suggesting a potential upside of 39.84%. CryoPort has a consensus price target of $14.44, suggesting a potential upside of 18.44%. Given Capricor Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Capricor Therapeutics is more favorable than CryoPort.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Capricor Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80
CryoPort
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.78

21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 92.9% of CryoPort shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by insiders. Comparatively, 10.0% of CryoPort shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

CryoPort beats Capricor Therapeutics on 11 of the 15 factors compared between the two stocks.

How does CryoPort compare to Galapagos?

Galapagos (NASDAQ:GLPG) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

In the previous week, CryoPort had 11 more articles in the media than Galapagos. MarketBeat recorded 17 mentions for CryoPort and 6 mentions for Galapagos. Galapagos' average media sentiment score of 0.72 beat CryoPort's score of -0.23 indicating that Galapagos is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Galapagos
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
CryoPort
3 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Galapagos has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, CryoPort has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500.

Galapagos has higher revenue and earnings than CryoPort. Galapagos is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galapagos$1.11B1.68$363.05M-$1.57N/A
CryoPort$176.18M3.47$78.30M$1.329.23

CryoPort has a net margin of 42.35% compared to Galapagos' net margin of 0.00%. Galapagos' return on equity of 0.00% beat CryoPort's return on equity.

Company Net Margins Return on Equity Return on Assets
GalapagosN/A N/A N/A
CryoPort 42.35%-8.22%-4.84%

Galapagos presently has a consensus price target of $36.50, suggesting a potential upside of 28.57%. CryoPort has a consensus price target of $14.44, suggesting a potential upside of 18.44%. Given Galapagos' higher possible upside, research analysts clearly believe Galapagos is more favorable than CryoPort.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galapagos
1 Sell rating(s)
5 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.14
CryoPort
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.78

32.5% of Galapagos shares are held by institutional investors. Comparatively, 92.9% of CryoPort shares are held by institutional investors. 2.9% of Galapagos shares are held by company insiders. Comparatively, 10.0% of CryoPort shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

CryoPort beats Galapagos on 10 of the 17 factors compared between the two stocks.

How does CryoPort compare to Inhibrx Biosciences?

CryoPort (NASDAQ:CYRX) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

CryoPort presently has a consensus target price of $14.44, suggesting a potential upside of 18.44%. Inhibrx Biosciences has a consensus target price of $150.00, suggesting a potential upside of 17.08%. Given CryoPort's stronger consensus rating and higher probable upside, equities analysts plainly believe CryoPort is more favorable than Inhibrx Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CryoPort
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.78
Inhibrx Biosciences
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.33

CryoPort has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of 3.88, indicating that its stock price is 288% more volatile than the S&P 500.

92.9% of CryoPort shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 10.0% of CryoPort shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, CryoPort had 12 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 17 mentions for CryoPort and 5 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.28 beat CryoPort's score of -0.23 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CryoPort
3 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Inhibrx Biosciences
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

CryoPort has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CryoPort$176.18M3.47$78.30M$1.329.23
Inhibrx Biosciences$1.30M1,439.58-$140.05M-$9.04N/A

CryoPort has a net margin of 42.35% compared to Inhibrx Biosciences' net margin of 0.00%. CryoPort's return on equity of -8.22% beat Inhibrx Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
CryoPort42.35% -8.22% -4.84%
Inhibrx Biosciences N/A -269.56%-71.94%

Summary

CryoPort beats Inhibrx Biosciences on 13 of the 17 factors compared between the two stocks.

How does CryoPort compare to Syndax Pharmaceuticals?

CryoPort (NASDAQ:CYRX) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

CryoPort has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500.

CryoPort presently has a consensus target price of $14.44, suggesting a potential upside of 18.44%. Syndax Pharmaceuticals has a consensus target price of $40.50, suggesting a potential upside of 101.49%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than CryoPort.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CryoPort
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.78
Syndax Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.86

In the previous week, Syndax Pharmaceuticals had 7 more articles in the media than CryoPort. MarketBeat recorded 24 mentions for Syndax Pharmaceuticals and 17 mentions for CryoPort. Syndax Pharmaceuticals' average media sentiment score of 0.35 beat CryoPort's score of -0.23 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CryoPort
3 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Syndax Pharmaceuticals
1 Very Positive mention(s)
5 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

CryoPort has higher earnings, but lower revenue than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CryoPort$176.18M3.47$78.30M$1.329.23
Syndax Pharmaceuticals$217.17M8.16-$285.42M-$2.79N/A

92.9% of CryoPort shares are owned by institutional investors. 10.0% of CryoPort shares are owned by insiders. Comparatively, 4.1% of Syndax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CryoPort has a net margin of 42.35% compared to Syndax Pharmaceuticals' net margin of -111.88%. CryoPort's return on equity of -8.22% beat Syndax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
CryoPort42.35% -8.22% -4.84%
Syndax Pharmaceuticals -111.88%-216.23%-43.50%

Summary

CryoPort beats Syndax Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get CryoPort News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CYRX vs. The Competition

Export
MetricCryoPortTRANS IndustryTransportation SectorNASDAQ Exchange
Market Cap$611.91M$6.70B$8.13B$11.87B
Dividend YieldN/A2.57%345.17%5.21%
P/E Ratio9.2318.9522.7628.47
Price / Sales3.471.844.6560.92
Price / CashN/A10.318.4036.52
Price / Book1.332.682.186.67
Net Income$78.30M$256.91M$533.74M$332.53M
7 Day Performance20.71%-3.44%0.55%2.01%
1 Month Performance39.00%2.27%4.56%9.19%
1 Year Performance110.54%4.81%40.37%39.59%

CryoPort Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CYRX
CryoPort
3.5372 of 5 stars		$12.19
+19.4%		$14.44
+18.4%		N/A$611.91M$176.18M9.231,186
PHVS
Pharvaris
3.007 of 5 stars		$29.83
+5.7%		$42.73
+43.2%		N/A$1.95BN/AN/A30
CAPR
Capricor Therapeutics
2.1668 of 5 stars		$32.46
-4.5%		$46.09
+42.0%		N/A$1.88BN/AN/A101
GLPG
Galapagos
2.9767 of 5 stars		$27.86
-2.0%		$36.50
+31.0%		N/A$1.84B$1.11BN/A1,310
INBX
Inhibrx Biosciences
1.696 of 5 stars		$124.82
-4.5%		$150.00
+20.2%		N/A$1.82B$1.30MN/A166

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CYRX) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel